Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp > re - Not good for the potential of apabetalone as a Covid-19

<< Previous

Bullboard Posts

Next >>

Comment by BearDownAZon Nov 30, 2021 12:59pm

141 Views

Post# 34180924

RE:re - Not good for the potential of apabetalone as a Covid-19

"thought we were NOT a pan-BET inhibitor? thought we hit BRD4, not both BRD3 and BRD4? or was it BRD2 and not both BRD3 and BRD4?"

My understanding of the published characterization of apabetalone is that it is not selective to BRD2, BRD3 or BRD4; however, it is more selective for binding to and inhibiting the second bromodomain (BD2) than BD1 irrespective of BRD2, BRD3 or BRD4. In other words, apabetalone can bind to and inhibit BRD2, BRD3 and BRD4, but it will bind BD2 more than BD1 on each of those.

BDAZ

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale